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ous abstinence rate and intervention costs were estimated. a dynamic population 
model for COPD was used to project the long-term (cost-)effectiveness of one year 
implementation of minimal counseling, intensive counseling and intensive counseling 
plus pharmacotherapy for 50% of the smoking COPD patients compared to usual 
care. Time horizon was 25 years. Uncertainty and one-way sensitivity analyses were 
performed for variations in (the calculation of) the abstinence rates, the type of projec-
tion, intervention costs and discount rates. RESULTS: Nine studies were selected. The 
average 12 months continuous abstinence rates were estimated to be 1.4% for usual 
care, 2.6% for minimal counseling, 6.0% for intensive counseling and 12.3% for 
pharmacotherapy. Compared to usual care, the costs per QALY gained for minimal 
counseling, intensive counseling and intensive counseling plus pharmacotherapy were 
c16,900, c8,200 and c2,400, respectively. Results were most sensitive to variations in 
abstinence rates and discount rates. CONCLUSIONS: Compared to usual care inten-
sive counseling and pharmacotherapy resulted in low costs per QALY gained with 
ratios comparable to results presented for smoking cessation in the general population. 
Compared to intensive counseling alone, intensive counseling plus pharmacotherapy 
was cost saving and dominated the other interventions.
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OBJECTIVES: The UPLIFT trial demonstrated in 5,993 patients with moderate to 
very-severe chronic obstructive pulmonary disease (COPD) that 4 years of tiotropium 
bromide were associated with improvements in lung function, quality of life, and 
exacerbations compared with placebo. The aim of this study is the economic assess-
ment of tiotropium when included in COPD routine care (RC) for speciﬁ c groups of 
Italian COPD patients. METHODS: A probabilistic patient-level simulation Markov 
model was developed over a lifetime horizon, with one-year cycles and a 3.5% annual 
discount rate. Patients were characterized by gender, age, height, smoking status and 
FEV1. FEV1 time trend was modelled based on the decline recorded in UPLIFT. The 
mortality of the general Italian population adjusted by smoking status and FEV1 was 
adopted. Health utilities derived from published Italian studies, while their variation 
from the UPLIFT. Exacerbation rates derived from an Italian observational prospec-
tive study and were adjusted for the relative risk (RR) reported in UPLIFT. Direct 
sanitary costs were considered. Health care resource consumption for RC, exacerba-
tions and SAEs derived from Italian observational studies and were valued according 
to current price and tariffs. Cost-effectiveness was assessed for the overall cohort and 
for subgroups of patients by age, sex, GOLD stage and smoking attitude. RESULTS: 
In the whole cohort, patients treated with tiotropium gained an average (95%CI) 0.50 
(−1.63– −6.27) LYs and 0.42 (−0.25– −3.05) QALYs with respect to RC. The incre-
mental lifetime cost was c3,357 (−c10,669– −c29,820). The incremental cost-effec-
tiveness ratio (ICER) was c7,916 /QALY. In the subgroups analysis the ICER ranged 
from a minimum of c6,627/QALY (females, GOLD III) to a maximum of c13,187/
QALY (age <65 y, GOLD IV). CONCLUSIONS: The inclusion of tiotropium in RC 
for moderate to very severe COPD patients represents good value for money in Italy. 
The analysis across subgroups demonstrated a good stability of the model.
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OBJECTIVES: In the Brazilian public health care system, mometasone furoate (MF 
DPI) is not available and budesonide/formoterol (BUD/FF DPI) association is respon-
sible for 86.9% of pharmacy claims for asthma. This study aimed to conduct cost-
effectiveness and budget impact analysis (BIA) of MF versus BUD/FF for adult patients 
with mild to moderate asthma from the public payer perspective. METHODS: A 
decision tree was developed to compare MF and BUD/FF based on indirect comparison 
once head-to-head studies were not available. The ﬁ nal FEV1 values were converted 
into probabilities of hospitalization in the ﬁ rst two years in accordance with observa-
tional evidence of association between FEV1 and exacerbation requiring hospitaliza-
tion. Only direct medical costs were considered and unit costs were obtained from 
Brazilian ofﬁ cial lists. BIA assumed pharmacy claims data from the Ambulatory 
Information System as current scenario (Beclomethasone: 3.1%; BUD: 9.9%; BUD/
FF: 86.9%) and a 20% initial market share for MF in substitution to equivalent doses 
of BUD/FF. RESULTS: Indirect comparison indicated 79 hospitalizations per 1000 
patients for MF and 82 for BUD/FF during the ﬁ rst 2 years of treatment. Total cost 
of treatment was 832BRL and 655BRL per patient for MF200 mcg twice a day (bid) 
and MF400 mcg once a day and 840BRL for BUD/FF 400/12 mcg bid. These ﬁ ndings 
indicated MF as cost-saving in the proposed scenario with ICER of −2.608BRL and 
−61.959BRL per avoided hospitalization for MF200 mcg and MF400 mcg, respec-
tively. The estimated budgetary impact for the ﬁ rst year showed a saving of 
259,346,480BRL for MF 400 mcg and 10,919,299BRL for MF 200 mcg. CONCLU-
SIONS: MF is a clinically effective option to treat mild to moderate asthma and 
indirect comparison showed its clinical and economic beneﬁ t when compared to the 
most used anti-asthma medication in the Brazilian public setting. Further research to 
directly compare both medications and to measure ﬁ nalistic outcomes alongside clini-
cal trials is needed.
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BACKGROUND: The phosphodiesterase-4 enzyme (PDE4) inhibitor roﬂ umilast is a 
new treatment that targets the underlying inﬂ ammation associated with COPD. When 
approved, roﬂ umilast will be registered as an add-on to bronchodilator treatment in 
adult patients with severe COPD, with a history of frequent exacerbations. a health 
economic (HE) micro-simulation Markov model was used to support its submission 
in the United Kingdom (UK). Pharmaceutical companies can save signiﬁ cantly on the 
process of HE evidence development, if models can be adapted for use in more than 
one country. OBJECTIVES: To transfer an existing UK HE model to the The Neth-
erlands in order to calculate the cost-effectiveness (CE) of roﬂ umilast in patients with 
severe COPD from a societal perspective. METHODS: The model structure was 
adapted to include production loss using the friction cost method, and to separate 
heterogeneity from parameter uncertainty. All input parameters on health care use, 
costs, utilities, and COPD epidemiology were obtained from Dutch sources, except 
for the case-fatality rate of an exacerbation-related hospitalization. a direct compari-
son was made between a combination of a long-acting β2 agonist (LABA) plus 
roﬂ umilast (ROFLU) and LABA alone. a second, indirect comparison was between 
LABA + ROFLU and LABA plus an inhaled corticosteroid (ICS). One-way and proba-
bilistic sensitivity analyses were performed. RESULTS: From a societal perspective, 
the incremental CE ratio (ICER) for LABA + ROFLU compared with LABA alone, 
was c7900. The ICER of LABA + ROFLU versus LABA + ICS was c10,000. The 
probability that LABA + ROFLU was cost-effective when compared with LABA alone 
at a threshold of c20,000 versus LABA was 97%. Compared with LABA + ICS this 
probability was 68.3%. CONCLUSIONS: The original UK model was suitable for 
adaptation to the Dutch setting. The ICERs of roﬂ umilast were below commonly 
referred threshold values of a QALY.
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OBJECTIVES: To estimate the incremental cost-effectiveness of SFC verus montelu-
kast in adult patients with persistent asthma. METHODS: A decision-analytic model 
was developed from a randomized, double-blind, double-dummy, 12-week clinical 
trial were analyzed. Efﬁ cacy end points included, symptom-free days (SFDs) during 
the 12-week period. The study assumed the Mexican health care perspective with costs 
in 2010 US dollars, and hence only direct costs were included in the analysis. Direct 
costs included those related to study drugs, emergency room department visits, 
unscheduled physician visits, and rescue medication. The incremental cost-effective-
ness ratio (ICER), which is the mean difference in average costs divided by the mean 
difference in average effectiveness, was calculated for the effectiveness outcomes 
(SFDs). Issue of uncertainty was addressed by means of a probabilistic Monte Carlo 
simulation, which attributed stochastic distributions to model inputs. RESULTS: 
Treatment with FSC resulted in a signiﬁ cantly greater improvement in the mean 
percentage of symptom-free days compared with MON 48.9 and 21.7 respectively (p 
0.001). In the base case, patients initiated on SFC displayed a 45% reduction in overall 
cost as compared with patients initiated on MON US S186 versus $US258, respec-
tively, respectively). SFC dominated the use of MON because of previously demon-
strated lower incidence of Asthma exacerbations and rescue free days. Sensitivity 
analyses determined that univariate changes in all model variables, including medica-
tion cost, and cost of treating exacerbation, did not impact overall results. a Monte 
Carlo simulation analysis found that use of SFC remains the best overall treatment 
strategy when taking into consideration the potential variance in all model assump-
tions. Compared with MON, SFC is estimated to be both more effective and more 
economically favourable, with a probability of almost 92%. CONCLUSIONS: The 
decision model indicated that use of SFC as treatment in patients with asthma should 
result in lower overall treatment costs relative to the cost of MON.
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OBJECTIVES: To assess the incremental cost-effectiveness of SFC compared with 
MON for the control of persistent asthma in children. METHODS: We conducted an 
economic evaluation on a 12-week prospective randomized open-label parallel-group 
